FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
03/19/2026
Back to search
Official data from USPTO
HARNESS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
HARNESS
ST13
US500000079398079Class
1, 5, 42
Filing
79398079
Registration
7895179
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
35
Latest update
04/03/2026
Trademark type
Word
Nice classes
1, 5, 42
Filing date
02/19/2024
Registration date
08/19/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/19/2025
Last transaction
04/03/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
GB
Examiner
KEENAN, CAYLA FAY
Law office
N40
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Harness Therapeutics Limited
Representatives
Rebecca Liebowitz Venable LLP
Technical classification
Nice Classes
Class 1Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicals for scientific purposes; chemicals for use in scientific research; chemicalsenzymesbiological preparations in the nature of DNA and RNA for scientific research use; chemicals for scientific research use in the preparation and creation of DNA and RNA; enzymes for scientific research purposes for use in the preparation and creation of DNA and RNA; molecular biology research tools in the nature of biologicalchemical and biochemical reagents for research use
Class 5
Pharmaceutical preparations for the treatment and prevention of ophthalmological conditionshearing losshematologic diseasesimmune response disordersneurological disorderspsychiatric disordersrespiratory diseasesfibrosishepatic diseasesrenal diseasesdiseases of the pancreasmetabolic diseasesgenetic conditionscancerinfectious diseases and cardiovascular diseases; medical and veterinary preparations for therapeutic purposes for the treatment and prevention of ophthalmological conditionshearing losshematologic diseasesimmune response disordersneurological disorderspsychiatric disordersrespiratory diseasesfibrosishepatic diseasesrenal diseasesdiseases of the pancreasmetabolic diseasesgenetic conditionscancerinfectious diseases and cardiovascular diseases; biologicalchemical and biochemical reagents for medical use; DNARNAoligonucleotidespolynucleotides for medical use; gene editing enzymes for medical use; medical preparations containing therapeutic DNA and RNAnucleic and sequences for medical purposes; all of the foregoing excluding dietary and nutritional supplements
Class 42
Scientific and technological services and research and design relating thereto namely scientific research services in the field of genomics; medical research services including the manipulation of biological reagents to be used for medical or therapeutic purposes; chemical and biological analysis and research services; scientific research into DNA and RNA; research and development into the creation of DNA and RNA; research and development services in the manufacture of synthetic DNARNAgenes and oligonucleotides for others; researchdevelopmenttesting and analysis for scientific research purposes in the field of genomicsDNA and RNA sequencinggene synthesisgene identificationgene cloninggene expressiongene mapping; scientific research in the field of molecular biologynext generation sequencinghigh-throughput sequencing and bioinformatics; gene-editing services for scientific research purposes; DNA and RNA modelling servicesgenetic mapping for scientific research purposes; gene engineering services; research and development services in the creation of genome libraries and collections of biologicals including chemicals and compounds; research and development services in creating libraries and collections of normal and mutated genes; scientific services research relating to the discoverypreclinical and clinical development of therapeutic productstherapeutic DNA and RNA; consultancy and advisory services relating to the aforesaid services
Publications
History of USPTO decisions and trademark events.
35 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
03/02/2026
FIMP
FINAL DISPOSITION PROCESSED
03/02/2026
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
12/05/2025
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
11/19/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
11/19/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
11/19/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/19/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
08/19/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/03/2025
PUBO
PUBLISHED FOR OPPOSITION
06/03/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/28/2025
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
05/06/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/15/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/02/2025
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
04/02/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/02/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/02/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/02/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/02/2025
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
03/21/2025
DOCK
ASSIGNED TO EXAMINER
03/19/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/14/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/14/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/14/2025
DOCK
ASSIGNED TO EXAMINER
11/30/2024
RFNT
REFUSAL PROCESSED BY IB
10/07/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/16/2024
RFRR
REFUSAL PROCESSED BY MPU
09/16/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
09/13/2024
CNRT
NON-FINAL ACTION WRITTEN
09/12/2024
DOCK
ASSIGNED TO EXAMINER
09/09/2024
MAFR
APPLICATION FILING RECEIPT MAILED
06/24/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/24/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/20/2024
Continuous trademark protection
Get notified about every new filing that threatens HARNESS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.